N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Price:
0.0001
JPY
Market Closed
Market Cap:
776 550.9T
JPY
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Nichi-Iko Pharmaceutical Co Ltd
0.0001
-3086.2889 (-100%)
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Nichi-Iko Pharmaceutical Co Ltd
Balance Sheet
Balance Sheet Decomposition
Nichi-Iko Pharmaceutical Co Ltd
Nichi-Iko Pharmaceutical Co Ltd
| Current Assets | 177.1B |
| Cash & Short-Term Investments | 13.3B |
| Receivables | 70.3B |
| Other Current Assets | 93.4B |
| Non-Current Assets | 69.4B |
| Long-Term Investments | 11.1B |
| PP&E | 35.9B |
| Intangibles | 22.2B |
| Other Non-Current Assets | 238m |
| Current Liabilities | 182.6B |
| Accounts Payable | 40.7B |
| Other Current Liabilities | 141.9B |
| Non-Current Liabilities | 99.7B |
| Long-Term Debt | 71.8B |
| Other Non-Current Liabilities | 27.9B |
Balance Sheet
Nichi-Iko Pharmaceutical Co Ltd
Nichi-Iko Pharmaceutical Co Ltd
Currency: JPY
| Mar-2013 | Mar-2014 | Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
5 309
|
21 695
|
14 032
|
28 179
|
12 457
|
18 529
|
42 093
|
42 944
|
29 142
|
15 305
|
|
| Cash Equivalents |
5 309
|
21 695
|
14 032
|
28 179
|
12 457
|
18 529
|
42 093
|
42 944
|
29 142
|
15 305
|
|
| Short-Term Investments |
0
|
1
|
0
|
0
|
366
|
974
|
447
|
425
|
3 715
|
425
|
|
| Total Receivables |
26 312
|
27 794
|
21 162
|
24 405
|
31 703
|
28 986
|
28 526
|
38 521
|
36 514
|
34 521
|
|
| Accounts Receivables |
26 312
|
27 794
|
21 162
|
24 405
|
29 311
|
27 219
|
26 573
|
36 045
|
33 762
|
32 731
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
2 392
|
1 767
|
1 953
|
2 476
|
2 752
|
1 790
|
|
| Inventory |
28 131
|
32 648
|
42 429
|
45 340
|
67 962
|
74 321
|
66 783
|
78 127
|
96 110
|
95 745
|
|
| Other Current Assets |
2 611
|
1 434
|
2 175
|
3 700
|
3 070
|
5 468
|
4 873
|
4 691
|
9 621
|
9 395
|
|
| Total Current Assets |
62 363
|
83 572
|
79 798
|
101 624
|
115 558
|
128 278
|
142 722
|
164 708
|
175 102
|
155 391
|
|
| PP&E Net |
30 412
|
29 750
|
34 107
|
38 786
|
47 417
|
54 045
|
55 710
|
59 201
|
68 943
|
39 289
|
|
| PP&E Gross |
0
|
0
|
34 107
|
0
|
47 417
|
54 045
|
55 710
|
59 201
|
68 943
|
39 289
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
35 927
|
39 556
|
44 587
|
49 932
|
55 727
|
82 965
|
|
| Intangible Assets |
2 857
|
2 276
|
3 575
|
5 845
|
50 131
|
45 735
|
46 721
|
56 607
|
56 957
|
39 609
|
|
| Goodwill |
1 514
|
1 287
|
1 077
|
634
|
40 486
|
38 536
|
42 892
|
44 322
|
45 661
|
18 479
|
|
| Note Receivable |
735
|
1 932
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
4 203
|
8 568
|
13 602
|
8 700
|
12 426
|
10 342
|
18 717
|
9 991
|
13 837
|
7 533
|
|
| Other Long-Term Assets |
837
|
1 745
|
1 298
|
920
|
2 882
|
1 428
|
76
|
1 990
|
3 072
|
258
|
|
| Other Assets |
1 514
|
1 287
|
1 077
|
634
|
40 486
|
38 536
|
42 892
|
44 322
|
45 661
|
18 479
|
|
| Total Assets |
102 921
N/A
|
129 130
+25%
|
139 834
+8%
|
161 128
+15%
|
268 900
+67%
|
278 364
+4%
|
306 838
+10%
|
336 819
+10%
|
363 572
+8%
|
260 559
-28%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
22 298
|
22 935
|
32 755
|
30 193
|
47 598
|
50 686
|
44 172
|
61 750
|
65 359
|
48 123
|
|
| Accrued Liabilities |
1 171
|
1 031
|
0
|
1 797
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
4 070
|
11 856
|
2 750
|
14 720
|
29 116
|
28 540
|
29 174
|
37 613
|
53 287
|
60 881
|
|
| Current Portion of Long-Term Debt |
3 769
|
4 478
|
4 902
|
4 723
|
8 080
|
6 959
|
8 261
|
9 134
|
9 826
|
24 648
|
|
| Other Current Liabilities |
7 574
|
6 421
|
9 690
|
12 829
|
8 569
|
11 209
|
10 230
|
14 193
|
15 102
|
13 819
|
|
| Total Current Liabilities |
38 883
|
46 721
|
51 618
|
64 262
|
93 363
|
97 394
|
91 837
|
122 690
|
143 574
|
147 471
|
|
| Long-Term Debt |
11 705
|
12 591
|
9 332
|
10 464
|
78 674
|
85 625
|
90 739
|
87 045
|
86 021
|
77 102
|
|
| Deferred Income Tax |
267
|
268
|
925
|
331
|
5 226
|
2 823
|
3 329
|
4 521
|
14 711
|
10 160
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1 343
|
1 268
|
379
|
|
| Other Liabilities |
3 256
|
3 355
|
3 472
|
3 474
|
8 466
|
4 980
|
4 610
|
5 393
|
6 831
|
12 053
|
|
| Total Liabilities |
54 111
N/A
|
62 935
+16%
|
65 347
+4%
|
78 531
+20%
|
185 729
+137%
|
190 822
+3%
|
190 515
0%
|
220 992
+16%
|
252 405
+14%
|
247 165
-2%
|
|
| Equity | |||||||||||
| Common Stock |
13 558
|
19 976
|
19 976
|
19 976
|
19 976
|
19 976
|
23 360
|
23 360
|
23 360
|
25 975
|
|
| Retained Earnings |
24 471
|
28 140
|
33 343
|
42 849
|
45 050
|
51 912
|
55 016
|
57 365
|
50 822
|
55 657
|
|
| Additional Paid In Capital |
12 274
|
18 678
|
18 684
|
18 796
|
18 845
|
18 827
|
21 896
|
21 896
|
21 896
|
24 511
|
|
| Unrealized Security Profit/Loss |
411
|
458
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Treasury Stock |
1 904
|
1 753
|
1 543
|
0
|
9 401
|
9 046
|
2 893
|
2 562
|
2 267
|
2 124
|
|
| Other Equity |
0
|
696
|
897
|
771
|
8 701
|
5 873
|
18 944
|
15 768
|
17 356
|
20 689
|
|
| Total Equity |
48 810
N/A
|
66 195
+36%
|
74 487
+13%
|
82 597
+11%
|
83 171
+1%
|
87 542
+5%
|
116 323
+33%
|
115 827
0%
|
111 167
-4%
|
13 394
-88%
|
|
| Total Liabilities & Equity |
102 921
N/A
|
129 130
+25%
|
139 834
+8%
|
161 128
+15%
|
268 900
+67%
|
278 364
+4%
|
306 838
+10%
|
336 819
+10%
|
363 572
+8%
|
260 559
-28%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
51
|
60
|
60
|
60
|
56
|
56
|
64
|
64
|
64
|
70
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
